Palvella Therapeutics earnings were -$49.3M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest PVLA earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$15.8M, up 24% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PVLA reported annual earnings of -$41.7M, with 139.3% growth.
Palvella Therapeutics Earnings Reports & History FAQ
What were Palvella Therapeutics's earnings last quarter?
Palvella Therapeutics (NASDAQ: PVLA) reported Q1 2026 earnings per share (EPS) of -$1.20, up 62.16% year over year. Total PVLA earnings for the quarter were -$15.77 million. In the same quarter last year, Palvella Therapeutics's earnings per share (EPS) was -$0.74.
Is Palvella Therapeutics profitable or losing money?
As of the last Palvella Therapeutics earnings report, Palvella Therapeutics is currently losing money. Palvella Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$49.30 million, a 113.56% increase year over year.
What was PVLA's earnings growth in the past year?
As of Palvella Therapeutics's earnings date in Q2 2026, Palvella Therapeutics's earnings has grown year over year. PVLA earnings in the past year totalled -$49.30 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.